Pfizer: Hospira One2One will operate alongside CentreSource, initially...

By Gareth Macdonald

- Last updated on GMT

Hospira site in Rocky Mount
Hospira site in Rocky Mount

Related tags Active ingredient Pharmacology

Hospira’s injectables contracting business will operate alongside Pfizer’s CentreSource services unit following the completion of the $17bn takeover deal last week.

The Hospira injectables unit – known as One2One – makes injectables has manufacturing facilities in McPherson, Kansas and Rocky Mount, North Carolina in the US.

The contract manufacturing organisation (CMO) also has production facilities in Liscate in Italy, Mulgrave in Australia, Chennai in India and Zagreb in Croatia.

A Pfizer spokeswoman told that the One2One business “will become part of Pfizer, but not part of CenterSource initially.”

The US drug giant also confirmed that all the One2One facilities, as well as the organisation’s head office in Lake Forest, Illinois will continue to operate independently.

When Pfizer announced plans for the $17bn (€15.2bn) takeover in February​ it cited Hospira’s generic injectables business along with its biosimilar development and production capabilities as the main drivers for the acquisition.

At the time Pfizer CEO Ian Read said: "Hospira’s business aligns well with our new commercial structure and is an excellent strategic fit for our Global Established Pharmaceutical business, which will benefit from a significantly enhanced product portfolio in growing markets​." 

Steroids and injectables

One2One provides contract custom development and finished-dose manufacturing of injectables to pharmaceutical industry customers.

Pfizer’s CentreSource business has a different focus.

The Pfizer division specialises in the production of steroid active pharmaceutical ingredients (APIs), antibiotics and the provision of custom manufacturing, process development and packaging services.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more